We tried to determine the incidence of the reactivation rates of chronic HBV and HCV infections in cancer patients who received different types of chemotherapy or immunosuppressive therapy. Also we tried to identify the chemotherapy regimens though to be associated with this reactivation of chronic HBV and HCV infections.
Between 2000 and 2014, 8322 cancer patients who were admitted to oncology departments were evaluated retrospectively and 3890 patients in whom hepatitis serology were available were included in this study. Their mortality rates, chemotherapy regimens, cancer types, number of positive hepatitis serology and reactivation rates were also obtained.
In all 8322 cancer patients, only 3890 (47%) patients had hepatitis serology results and 355 patients had positive hepatitis serology results (HBsAg, anti-HBcAg, anti-HCV). Of them, 4.24% had anti-HBcAg positivity, 3.65%had HBsAg positivity, and 1.23% had anti-HCV positivity. Nineteen patients with HBsAg positive (13.38%), 4 patients with anti-HBcAg positive (2.42%), and 2 patients with anti-HCV positive (4.16%) had reactivation. hepatitis reactivation was seen significantly higher in lymphoma patients (p = 0.032). Reactivation rate of hepatitis B in those patients (HBsAg positive) was detected as 57.14%. In patients with hepatitis reactivation, the rates of usage of 5-FU, cisplatin, cyclophosphamide, doxorubicin, steroid, rituximab, and vincristine were determined as significantly higher than patients with positive hepatitis serology results but without hepatitis reactivation (p > 0.05 for all).
An association between hepatitis reactivation and the usage of 5-FU, cisplatin, cyclophosphamide, doxorubicin, steroid, rituximab, and vincristine was detected. Thus physicians should consider antiviral prophylaxis before initiating these chemotherapeutics.
Clinical trial identification
Legal entity responsible for the study
Individuals: Ahmet Ozet, Deniz Tural
All authors have declared no conflicts of interest.